Canaccord Genuity Group Has Lowered Expectations for Merit Medical Systems (NASDAQ:MMSI) Stock Price

Merit Medical Systems (NASDAQ:MMSI) had its price objective cut by research analysts at Canaccord Genuity Group from $90.00 to $85.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 37.07% from the company’s previous close.

Several other research analysts have also recently commented on the stock. Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Piper Sandler lowered their target price on shares of Merit Medical Systems from $106.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Barrington Research dropped their price objective on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a report on Monday, April 20th. Compass Point set a $107.00 price objective on Merit Medical Systems in a report on Monday, April 20th. Finally, JPMorgan Chase & Co. dropped their price objective on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a report on Friday. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $92.80.

Merit Medical Systems Stock Performance

Shares of MMSI stock traded down $6.17 on Friday, hitting $62.01. The company’s stock had a trading volume of 2,526,188 shares, compared to its average volume of 777,070. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.95 and a current ratio of 4.34. The stock’s 50 day moving average is $70.68 and its 200-day moving average is $79.78. Merit Medical Systems has a fifty-two week low of $61.31 and a fifty-two week high of $100.19. The company has a market capitalization of $3.70 billion, a PE ratio of 29.25, a PEG ratio of 1.83 and a beta of 0.64.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, beating the consensus estimate of $0.96 by $0.08. Merit Medical Systems had a net margin of 8.48% and a return on equity of 13.82%. The business had revenue of $393.94 million for the quarter, compared to the consensus estimate of $390.77 million. During the same period in the prior year, the company posted $0.93 earnings per share. Merit Medical Systems’s revenue was up 10.9% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Equities research analysts expect that Merit Medical Systems will post 3.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MMSI. Los Angeles Capital Management LLC bought a new position in Merit Medical Systems in the fourth quarter valued at approximately $25,000. Maseco LLP bought a new position in Merit Medical Systems in the 4th quarter valued at approximately $26,000. Salomon & Ludwin LLC acquired a new stake in shares of Merit Medical Systems during the 3rd quarter valued at $37,000. Torren Management LLC acquired a new stake in shares of Merit Medical Systems during the 4th quarter valued at $38,000. Finally, Covestor Ltd boosted its holdings in shares of Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 336 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

Merit Medical Systems News Summary

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q1 results beat and management raised guidance — Merit reported Q1 non?GAAP EPS of $0.94 (vs. $0.84 est.) and revenue of ~$382M (beat). The company lifted FY2026 EPS guidance to $4.01–$4.15 and reiterated revenue targets, pointing to steady segment/geographic gains and improved margins and free cash flow. Press Release
• Positive Sentiment: Operational highlights support durable cash generation — Management reported GAAP operating margin ~11.6%, non?GAAP operating margin ~19.7%, and free cash flow up ~26%. These metrics support the company’s cash?flow story and capital deployment (recent acquisition activity). Details
• Positive Sentiment: Acquisition expands product set — Merit closed the View Point Medical acquisition (OneMark detection/tissue marker products) for $140M (cash portion $90M), and divested the DualCap line for $28M; these moves can bolster higher?margin therapeutic offerings. Transaction Details
• Neutral Sentiment: Earnings call / transcripts available — Call transcripts and highlights confirm beat and management commentary on organic growth, mix, and margin drivers; useful for investors who want management color. Earnings Call Transcript
• Negative Sentiment: Analysts trimmed price targets — Several firms cut PTs today (JPMorgan: $95?$77, Wells Fargo: $78?$74, Needham: $101?$90). Although ratings were maintained (overweight/equal weight/buy), the cuts reflect multiple?compression or sector re?rating concerns and likely contributed to selling pressure. Analyst Notes (Benzinga)
• Negative Sentiment: Market reaction driven by valuation vs. growth — Despite beats, some analysts flagged growth deceleration and applied lower sector multiples; with the stock already well off its 52?week high, target trims can trigger headline-driven outflows. Analyst Commentary

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.